No 03 2016

Swedish medtech company NanoEcho has been declared bankrupt after failing to find a solution to its strained financial situation.

A study of Ukrainian combat veterans with limb loss reports 97.9% implant survival one year after completion of treatment with Integrum’s OPRA Implant System, a bone-anchored prosthesis.

Swedish biosimilar developer Xbrane Biopharma has fully recruited the pivotal clinical trial of Xdivane, its biosimilar candidate to Bristol Myers Squibb's cancer immunotherapy Opdivo (nivolumab).

Zealand Pharma has entered a collaboration and license agreement with Generate Biomedicines to develop AI-engineered multispecific protein therapeutics for obesity and other metabolic diseases. Generate is eligible for nearly USD 1.2 billion in milestones for the first two programs.

For bladder cancer patients, the hardest part of treatment is often not knowing whether it will work. At Karolinska Institutet and SciLifeLab, researchers are developing tools that read a tumor's own molecular signals to predict who will benefit from novel systemic therapies – before treatment even begins.

Stockholm-based healthtech company Encare has signed an agreement with the National Cancer Institute of Thailand (NCI Thailand) to support the implementation of Enhanced Recovery After Surgery (ERAS) in colorectal surgery. The Bangkok institute, which operates under Thailand’s Ministry of Public Health, is Encare’s first hospital partner in the country.

Women vaccinated against HPV before their first pregnancy were less likely to give birth prematurely, according to a Swedish register study from Karolinska Institutet published in The BMJ.